It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.

Biosimilars can help reduce the high cost of oncology medicines spending1

Oncology innovation is booming, but costly for the healthcare system1,2

U.S. oncology medicine spending may rise up to 105 billion by 2023, with anticipated growth between 11 and 14% per year

*Costs through 2018 are based on data reported by the IQVIA Institute for Human Data Science from December 2018. Costs beyond 2018 are projected growth based on a CAGR of 11% to 14% in the next 4 years.2

Biosimilars callout

Learn about Ziextenzo (pegfilgrastim-bmez), the long-acting G-CSF treatment option from Sandoz4

CAGR=compound annual growth rate; G-CSF=granulocyte colony-stimulating factor.

References: 1. IQVIA Institute for Human Data Science. Global oncology trends 2018: innovation, expansion and disruption. Accessed January 13, 2021. 2. IQVIA Institute for Human Data Science. Global oncology trends 2019: therapeutics, clinical development and health system implications. Accessed January 13, 2021. 3. Socal M, Ballreich J, Chyr L, Anderson G. Biosimilar medications – savings opportunities for large employers: a report for ERIC – the ERISA Industry Committee. Department of Health Policy and Management. John Hopkins Bloomberg School of Public Health. March 2020. 4. ZIEXTENZO Prescribing Information. Sandoz Inc. March 2021.